Logo

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

Share this

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

Shots:

  • The P-II ELARA study involves assessing the efficacy & safety of Kymriah in adult patients with r/r FL in 30 sites across 12 countries
  • Results: @median follow-up of 11 mos.- CRR (66%)- ORR (86%) with one-time therapy infusion- median DOR in all responders- PFS & OS were not reached- response rates were consistent across high-risk patient subgroups- estimated DOR in patients with CR and PFS rates @6mos. (94% & 76%)- no patient experienced grade 3/4 cytokine release syndrome. The regulatory submissions based on a P-II study is expected in late 2021
  • Kymriah is 1st FDA-approved CAR-T cell therapy for r/r ALL in pediatric & adult patients and r/r adult DLBCL

  Ref: Globe Newswire | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions